Central Pharmaceuticals Ltd. (DSE: CENTRALPHL)
Bangladesh
· Delayed Price · Currency is BDT 8.90
+0.10 (1.14%)
At close: Nov 14, 2024
Central Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 111.75 | 29.33 | 26 | 148.15 | 140.09 | 307.47 | Upgrade
|
| Revenue Growth (YoY) | - | 12.81% | -82.45% | 5.75% | -54.44% | -3.79% | Upgrade
|
| Cost of Revenue | 126.9 | 58.36 | 63.58 | 118.89 | 629.42 | 164.07 | Upgrade
|
| Gross Profit | -15.15 | -29.03 | -37.58 | 29.27 | -489.33 | 143.39 | Upgrade
|
| Selling, General & Admin | 29.99 | 18.83 | 15.77 | 22.45 | 610.55 | 44.62 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | 0.03 | Upgrade
|
| Operating Expenses | 29.99 | 18.83 | 15.77 | 22.45 | 610.55 | 44.65 | Upgrade
|
| Operating Income | -45.14 | -47.86 | -53.35 | 6.82 | -1,100 | 98.75 | Upgrade
|
| Interest Expense | -18.11 | - | -17.36 | -21.36 | -9.95 | -35.63 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.11 | -0.09 | -0.03 | -0.07 | Upgrade
|
| Pretax Income | -63.26 | -47.87 | -70.82 | -14.63 | -1,110 | 63.04 | Upgrade
|
| Income Tax Expense | -4.09 | -3.91 | -2.57 | -6.16 | -2.85 | 5.95 | Upgrade
|
| Net Income | -59.17 | -43.96 | -68.25 | -8.47 | -1,107 | 57.09 | Upgrade
|
| Net Income to Common | -59.17 | -43.96 | -68.25 | -8.47 | -1,107 | 57.09 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -6.26% | Upgrade
|
| Shares Outstanding (Basic) | 123 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Change (YoY) | 2.36% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.48 | -0.37 | -0.57 | -0.07 | -9.24 | 0.48 | Upgrade
|
| EPS (Diluted) | -0.48 | -0.37 | -0.57 | -0.07 | -9.24 | 0.48 | Upgrade
|
| EPS Growth | - | - | - | - | - | -6.26% | Upgrade
|
| Free Cash Flow | -0.13 | -0.33 | -1.12 | -4.78 | -0.41 | -0.93 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.04 | -0.00 | -0.01 | Upgrade
|
| Dividend Per Share | - | - | - | - | - | 0.100 | Upgrade
|
| Gross Margin | -13.56% | -98.99% | -144.57% | 19.75% | - | 46.64% | Upgrade
|
| Operating Margin | -40.40% | -163.18% | -205.21% | 4.60% | -785.11% | 32.12% | Upgrade
|
| Profit Margin | -52.95% | -149.88% | -262.51% | -5.72% | -790.20% | 18.57% | Upgrade
|
| Free Cash Flow Margin | -0.11% | -1.11% | -4.31% | -3.22% | -0.29% | -0.30% | Upgrade
|
| EBITDA | -20.65 | -21.11 | -23.59 | 39.71 | -1,064 | 138.82 | Upgrade
|
| EBITDA Margin | -18.48% | -71.98% | -90.75% | 26.80% | - | 45.15% | Upgrade
|
| D&A For EBITDA | 24.49 | 26.75 | 29.76 | 32.89 | 36.28 | 40.07 | Upgrade
|
| EBIT | -45.14 | -47.86 | -53.35 | 6.82 | -1,100 | 98.75 | Upgrade
|
| EBIT Margin | -40.40% | -163.18% | -205.21% | 4.60% | - | 32.12% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 9.44% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.